ADVERSE IMPACT OF MILD HYPERTENSION POST TRANSPLANT ON 1 YEAR CHRONIC INTERSTIAL FIBROSIS AND TUBULAR ATROPY SCORES IN KIDNEY ALLOGRAFT BIOPSY AMONG A COHORT ON RAPID STEROID WITHDRAWL PROTOCOL.

2010 ◽  
Vol 90 ◽  
pp. 387
Author(s):  
H. Chakkera ◽  
Y. Devarapalli ◽  
D. Mulligan ◽  
M. Mazur ◽  
K. Hamawi ◽  
...  
Keyword(s):  
Mild Hypertension ◽  
Adverse Impact ◽  
Kidney Allograft ◽  
Post Transplant ◽  
Allograft Biopsy

scholarly journals Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients

Pharmaceutics ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 413
Author(s):  
Theerawut Klangjareonchai ◽  
Natsuki Eguchi ◽  
Ekamol Tantisattamo ◽  
Antoney J. Ferrey ◽  
Uttam Reddy ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Kidney Transplantation ◽  
Kidney Transplant ◽  
Pharmacological Intervention ◽  
Diabetic Patients ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Kidney Allograft ◽  
Post Transplant ◽  
Glucose Management

Hyperglycemia after kidney transplantation is common in both diabetic and non-diabetic patients. Both pretransplant and post-transplant diabetes mellitus are associated with increased kidney allograft failure and mortality. Glucose management may be challenging for kidney transplant recipients. The pathophysiology and pattern of hyperglycemia in patients following kidney transplantation is different from those with type 2 diabetes mellitus. In patients with pre-existing and post-transplant diabetes mellitus, there is limited data on the management of hyperglycemia after kidney transplantation. The following article discusses the nomenclature and diagnosis of pre- and post-transplant diabetes mellitus, the impact of transplant-related hyperglycemia on patient and kidney allograft outcomes, risk factors and potential pathogenic mechanisms of hyperglycemia after kidney transplantation, glucose management before and after transplantation, and modalities for prevention of post-transplant diabetes mellitus.

scholarly journals High urinary interleukin-2 in late post-transplant period portends a risk of decline in kidney allograft function: a preliminary study

2017 ◽  
Vol 10 (1) ◽  
Author(s):  
Andriy V. Trailin ◽  
Marina V. Pleten ◽  
Tetyana I. Ostapenko ◽  
Nadiia F. Iefimenko ◽  
Olexandr S. Nykonenko
Keyword(s):  
Interleukin 2 ◽  
Kidney Allograft ◽  
Post Transplant ◽  
Allograft Function ◽  
Preliminary Study

Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection

2008 ◽  
Vol 41 (3) ◽  
pp. 687-693 ◽  
Author(s):  
Mohsen Nafar ◽  
Farhat Farrokhi ◽  
Mohammad Vaezi ◽  
Amir-Ebrahim Entezari ◽  
Fatemeh Pour-Reza-Gholi ◽  
...  
Keyword(s):  
Allograft Rejection ◽  
Kidney Allograft ◽  
Post Transplant ◽  
Soluble Cd30 ◽  
Kidney Allograft Rejection

INCIDENCE OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN KIDNEY ALLOGRAFT PATIENTS

1998 ◽  
Vol 65 (Supplement) ◽  
pp. 226
Author(s):  
M. Schult ◽  
V. Kliem ◽  
H. J. Schlitt ◽  
R. Brunkhorst ◽  
B. Nashan
Keyword(s):  
Lymphoproliferative Disorders ◽  
Kidney Allograft ◽  
Post Transplant

scholarly journals Histopathological evaluation of renal allograft biopsies in Nepal: interpretation and significance

1970 ◽  
Vol 2 (3) ◽  
pp. 172-179
Author(s):  
G Aryal ◽  
DS Shah
Keyword(s):  
T Cell ◽  
Renal Allograft ◽  
Calcineurin Inhibitor ◽  
Viral Infections ◽  
Ischemic Injury ◽  
Graft Dysfunction ◽  
Post Transplant ◽  
Medical College ◽  
Antibody Mediated Rejection ◽  
Allograft Biopsy

Background:  Renal allograft biopsy remains the gold standard for the diagnosis of graft dysfunction. Protocol renal allograft biopsies have provided insights into pathogenesis of early and late allograft injury and guided clinical management. The aim of this study was to find out the causes of early and late graft dysfunction in renal allograft biopsies taken at different time points after transplantation. Materials and Methods: Between August 2008 and February 2011, a total of 98 renal allograft biopsies from 62 kidney transplants recipients were received in the department of Pathology, KIST Medical College and Teaching Hospital. Renal allograft biopsies were interpreted according to the Schemes of Banff ’09 update. Results: The maximum numbers of recipients were in the age group of 31-40 years. Age ranges from 16 to 61 years. Out of 62 recipients, there were 47(75.8%) males and 15 (24.2%) females. The time of biopsy ranges from 0 hour to 6 years after transplantation. There were 9 (9.18%) cases of acute T cell-mediated rejection, 8 (8.16%) cases of acute antibody-mediated rejection, 6 (6.12%) cases of acute ischemic injury, 6 (6.12%) cases of borderline lesions and 4 (4.08%) cases of chronic calcineurin inhibitor toxicity. Conclusion: In the early post-transplant period (0-6 months), acute antibody-mediated rejection, acute ischemic injury and T cell-mediated rejection are the major causes for graft dysfunction. In the late post transplant period (> 6 months after transplant), transplant glomerulopathy, chronic calcineurin inhibitor toxicity, viral infections and graft senescence including donor derived disease result in poor late graft survival.DOI: http://dx.doi.org/10.3126/jpn.v2i3.6016 JPN 2012; 2(3): 172-179

INCIDENCE OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN KIDNEY ALLOGRAFT PATIENTS

1998 ◽  
Vol 65 (12) ◽  
pp. S150
Author(s):  
M. Schult ◽  
V. Kliem ◽  
H. J. Schlitt ◽  
R. Brunkhorst ◽  
B. Nashan
Keyword(s):  
Lymphoproliferative Disorders ◽  
Kidney Allograft ◽  
Post Transplant

scholarly journals Chemokine CXCL13 as a New Systemic Biomarker for B-Cell Involvement in Acute T Cell-Mediated Kidney Allograft Rejection

2019 ◽  
Vol 20 (10) ◽  
pp. 2552 ◽  
Author(s):  
Lena Schiffer ◽  
Flavia Wiehler ◽  
Jan Hinrich Bräsen ◽  
Wilfried Gwinner ◽  
Robert Greite ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Severe Disease ◽  
Serum Levels ◽  
Clinical Findings ◽  
Blood Levels ◽  
Kidney Allograft ◽  
Cell Clusters ◽  
Allograft Biopsy ◽  
Patients At Risk

The presence of B-cell clusters in allogenic T cell-mediated rejection (TCMR) of kidney allografts is linked to more severe disease entities. In this study we characterized B-cell infiltrates in patients with TCMR and examined the role of serum CXCL-13 in these patients and experimentally. CXCL-13 serum levels were analyzed in 73 kidney allograft recipients at the time of allograft biopsy. In addition, four patients were evaluated for CXCL13 levels during the first week after transplantation. ELISA was done to measure CXCL-13 serum levels. For further mechanistic understanding, a translational allogenic kidney transplant (ktx) mouse model for TCMR was studied in BalbC recipients of fully mismatched transplants with C57BL/6 donor kidneys. CXCL-13 serum levels were measured longitudinally, CD20 and CD3 composition and CXCL13 mRNA in tissue were examined by flow cytometry and kidneys were examined by histology and immunohistochemistry. We found significantly higher serum levels of the B-cell chemoattractant CXCL13 in patients with TCMR compared to controls and patients with borderline TCMR. Moreover, in patients with acute rejection within the first week after ktx, a >5-fold CXCL13 increase was measured and correlated with B-cell infiltrates in the biopsies. In line with the clinical findings, TCMR in mice correlated with increased systemic serum-CXCL13 levels. Moreover, renal allografts had significantly higher CXCL13 mRNA expression than isogenic controls and showed interstitial CD20+ B-cell clusters and CD3+ cell infiltrates accumulating in the vicinity of renal vessels. CXCL13 blood levels correlate with B-cell involvement in TCMR and might help to identify patients at risk of a more severe clinical course of rejection.

Sign in / Sign up

Export Citation Format

Share Document